```html

Extremity Deep Vein Thrombosis (DVT) – A Complete Patient Guide

Overview

Deep vein thrombosis (DVT) is the formation of a blood clot (thrombus) in a deep vein, most often in the legs or pelvis. When the clot occurs in an arm, it is still called DVT but is less common. The term “extremity DVT” therefore refers to clots in the deep veins of either the lower or upper limbs.

Why it matters: If a clot breaks free, it can travel to the lungs and cause a pulmonary embolism (PE), a life‑threatening emergency. Even when PE does not occur, DVT can lead to chronic swelling, pain, and a condition called post‑thrombotic syndrome.

Who it affects

• Adults over 45 are at highest risk, but DVT can occur at any age.
• Women have a slightly higher lifetime risk than men, partly because of pregnancy, hormone therapy, and oral contraceptives.
• People with certain inherited clotting disorders (e.g., Factor V Leiden) are predisposed.

Prevalence

• In the United States, about 900,000 cases of DVT and PE occur each year, with roughly CDC estimating a 1‑2 per 1,000 annual incidence of DVT.<sup>1</sup>
• Upper‑extremity DVT accounts for 4‑10% of all DVT cases, often related to central venous catheters or vigorous activity.<sup>2</sup>

Symptoms

Symptoms can range from subtle to severe. Not every person experiences all of them, and some DVTs are discovered incidentally on imaging done for another reason.

• Pain or tenderness – usually in the calf, thigh, or arm, worsening when standing or walking.
• Swelling (edema) – often one‑leg or one‑arm swelling compared with the opposite side.
• Warmth – the affected area may feel hotter than surrounding skin.
• Redness or discoloration – a bluish or reddish hue can develop, especially in the ankle or forearm.
• Visible surface veins – superficial veins may become more prominent as blood is rerouted around the clot.
• Leg heaviness or cramping – a sensation of “heaviness” that improves with leg elevation.
• Homan’s sign (rarely used) – pain on forced dorsiflexion of the foot; not reliable alone.
• Chest pain, shortness of breath, rapid heartbeat – these are signs of a possible PE and require immediate care (see “When to Seek Emergency Care”).

Causes and Risk Factors

DVT develops when three elements of Virchow’s triad converge: stasis of blood flow, endothelial injury, and hypercoagulability. Below are the most common contributors.

1. Venous Stasis

• Prolonged immobility (e.g., long‑distance travel, postoperative bed rest, casting).
• Obesity – excess weight increases pressure on veins.
• Varicose veins or chronic venous insufficiency.

2. Endothelial Injury

• Trauma or fractures to the limb.
• Orthopedic surgery, especially hip or knee replacement.
• Insertion of central venous catheters, pacemaker leads, or peripherally inserted central catheters (PICCs).

3. Hypercoagulability

• Genetic clotting disorders (Factor V Leiden, prothrombin G20210A, protein C/S deficiency).
• Cancer and its treatments (chemotherapy, hormonal therapy).
• Pregnancy, postpartum period, estrogen‑containing contraceptives or hormone replacement therapy.
• Autoimmune diseases (e.g., antiphospholipid antibody syndrome).
• Severe infections or inflammatory states (e.g., COVID‑19).

Additional Risk Factors

• Age > 60 years.
• Smoking.
• Previous DVT or PE.
• Family history of venous thromboembolism.
• Dehydration (reduces plasma volume, increasing clot tendency).

Diagnosis

Because untreated DVT can be fatal, clinicians use a stepwise approach to confirm the diagnosis quickly and safely.

1. Clinical Assessment – Wells Score

The Wells clinical prediction rule assigns points for signs, symptoms, and risk factors. Scores categorize patients as low, moderate, or high probability for DVT, guiding further testing.

2. Compression Ultrasonography

• Doppler ultrasound is the first‑line imaging test; it visualizes clot presence, vein compressibility, and blood flow.
• For suspected proximal DVT (femoral, popliteal), a single‑view compression study is >95% sensitive.
• Repeated scanning in 5–7 days may be used if initial study is equivocal.

3. D‑dimer Blood Test

• A fibrin degradation product that rises when clotting and lysis occur.
• High sensitivity but low specificity – a normal D‑dimer in a low‑risk patient can safely exclude DVT.

4. Advanced Imaging (when ultrasound is inconclusive)

• CT venography or MR venography – useful for pelvic or upper‑extremity veins.
• Contrast venography – gold standard but invasive; rarely needed today.

5. Laboratory Work‑up for Underlying Causes

• Complete blood count, basic metabolic panel.
• Coagulation profile (PT/INR, aPTT) if anticoagulation therapy is being considered.
• Tests for inherited thrombophilia in selected patients (e.g., recurrent DVT, family history).

Treatment Options

The primary goals are to prevent clot extension, reduce the risk of PE, and lower the chance of long‑term complications.

Anticoagulation – First‑Line Therapy

• Direct oral anticoagulants (DOACs) – rivaroxaban, apixaban, edoxaban, and dabigatran are now preferred for most patients because they require no routine INR monitoring. Typical duration: 3 months for provoked DVT; extended therapy (≥6 months or indefinite) for unprovoked or high‑risk cases.<sup>3</sup>
• Low‑molecular‑weight heparin (LMWH) – enoxaparin or dalteparin injected subcutaneously. Often used as a bridge when starting warfarin or when DOACs are contraindicated (e.g., severe renal impairment).
• Warfarin – vitamin K antagonist; INR target 2.0–3.0. Requires frequent blood tests and dietary consistency.
• Unfractionated heparin (UFH) – IV infusion; reserved for patients with high bleeding risk or those needing rapid reversal (e.g., before surgery).

Thrombolytic Therapy

Considered for massive proximal DVT with severe limb swelling or threatened limb viability, and when the risk of major bleeding is acceptable. Options include catheter‑directed alteplase or systemic thrombolysis.

Mechanical Interventions

• Catheter‑directed thrombectomy – physical removal of clot; used in selected cases.
• Inferior vena cava (IVC) filter – placed in the IVC to catch emboli when anticoagulation is contraindicated. Filters should be retrieved when no longer needed to avoid long‑term complications.

Adjunctive Measures

• Compression stockings (30‑40 mmHg) – reduce swelling and lower risk of post‑thrombotic syndrome when worn for 2 years after a proximal DVT (evidence mixed; discuss with your provider).
• Early ambulation – gentle walking as soon as pain allows; helps prevent stasis.
• Analgesics – acetaminophen or short‑course NSAIDs for pain, unless contraindicated.

Living with Extremity Deep Vein Thrombosis (DVT)

Managing DVT is a partnership between you and your healthcare team. Below are practical tips for day‑to‑day life.

Medication Adherence

• Take anticoagulants exactly as prescribed; never skip a dose.
• Set daily reminders (phone alarms, pillboxes).
• Inform ALL providers (dentist, surgeon, pharmacist) that you are on anticoagulation.

Monitoring for Bleeding

• Watch for unusual bruising, nosebleeds, gum bleeding, or dark stools.
• Report any signs of internal bleeding (e.g., severe abdominal pain, coughing up blood) immediately.

Lifestyle Adjustments

• Stay hydrated – aim for ≥ 2 L of water daily unless fluid‑restricted.
• Maintain a healthy weight; even modest weight loss can lower clot risk.
• Engage in regular low‑impact exercise (walking, stationary cycling) 30 min most days.
• Avoid prolonged sitting: stand and move every 1–2 hours during travel or desk work.

Foot and Leg Care

• Elevate the affected limb above heart level for 15 minutes, 3–4 times daily to reduce swelling.
• Inspect skin daily for redness, sores, or ulcers—important for those with chronic edema.
• Wear properly fitting shoes; avoid tight hosiery that may worsen venous stasis.

Follow‑up Appointments

• First follow‑up is usually 1‑2 weeks after starting anticoagulation to assess response and side effects.
• Subsequent visits at 3 months, 6 months, and then annually, or sooner if symptoms change.
• Blood tests (e.g., CBC, renal function) are needed periodically while on certain anticoagulants.

Prevention

Even after a DVT resolves, you can lower the chance of recurrence.

• Pharmacologic prophylaxis – Low‑dose aspirin (81 mg) or a reduced‑dose DOAC may be recommended for high‑risk patients after the initial treatment period.
• Compression therapy – Graduated compression stockings during long trips or after surgery.
• Mobility – Get up and move within the first 24 hours after any surgery or hospital stay.
• Pregnancy‑specific measures – Prenatal vitamins with adequate folic acid, regular prenatal check‑ups, and, when indicated, low‑dose LMWH during high‑risk pregnancies.
• Avoid smoking – Smoking cessation reduces overall clotting tendency.

Complications

Prompt treatment dramatically reduces risk, but untreated or poorly managed DVT can lead to serious outcomes.

• Pulmonary embolism (PE) – Clot travels to lungs; can cause sudden shortness of breath, chest pain, or death.
• Post‑thrombotic syndrome (PTS) – Chronic pain, swelling, skin changes, and ulceration in the affected limb; occurs in up to 30‑50% of patients with proximal DVT.<sup>4</sup>
• Recurrent DVT – Prior clot increases risk of another clot by 10‑20% per year.
• Venous insufficiency – Damaged valves from the clot lead to long‑term venous hypertension.
• Bleeding complications – From anticoagulant therapy; gastrointestinal or intracranial bleeding is rare but serious.

When to Seek Emergency Care

---

Sources:
1. Centers for Disease Control and Prevention (CDC). “Data & Statistics on Deep Vein Thrombosis.” https://www.cdc.gov/ncbddd/dvt/data.html.
2. Kearon C, et al. “Upper‑extremity deep vein thrombosis: epidemiology, risk factors, and management.” J Thromb Haemost. 2021;19:1125‑1135.
3. American College of Chest Physicians (CHEST). “Antithrombotic Therapy for VTE Disease: 9th ed.” Chest. 2021;149(2):315‑352.
4. Kahn SR, et al. “Post‑thrombotic syndrome after deep‑vein thrombosis.” Ann Intern Med. 2020;172(9):629‑638.
Additional information adapted from Mayo Clinic, NIH National Heart, Lung, & Blood Institute, and WHO guidelines.

```